3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
3
Thoracic
2
Head & Neck
1
Dermatologic
1
Breast
1
Conditions
Melanoma
14
Carcinoma, Non-Small-Cell Lung
8
Head and Neck Neoplasms
5
Carcinoma, Renal Cell
5
Triple Negative Breast Neoplasms
3
Skin Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Motor Activity
1
Mesothelioma, Malignant
1
Lung Neoplasms
1
Kidney Neoplasms
1
Gastrointestinal Neoplasms
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
27
Nivolumab
20
atezolizumab
6
Ipilimumab
6
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Paclitaxel
4
Docetaxel
4
Cyclophosphamide
4
Carboplatin
4
fludarabine
3
avelumab
3
Pemetrexed
3
Interleukin-2
3
tislelizumab
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Radiosurgery
2
Cisplatin
2
veliparib
1
toripalimab
1
spartalizumab
1
sotigalimab
1
sonidegib
1
sargramostim
1
regorafenib
1
poly ICLC
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Immune Checkpoint Inhibitors
×
Dermatologic
×
Clear all
NCT03511391
2024-01-23
CHEERS
University Hospital, Ghent
Phase 2
Completed
99 enrolled